Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 8

1.

Longitudinal immune characterization of syngeneic tumor models to enable model selection for immune oncology drug discovery.

Taylor MA, Hughes AM, Walton J, Coenen-Stass AML, Magiera L, Mooney L, Bell S, Staniszewska AD, Sandin LC, Barry ST, Watkins A, Carnevalli LS, Hardaker EL.

J Immunother Cancer. 2019 Nov 28;7(1):328. doi: 10.1186/s40425-019-0794-7.

2.

Local checkpoint inhibition of CTLA-4 as a monotherapy or in combination with anti-PD1 prevents the growth of murine bladder cancer.

van Hooren L, Sandin LC, Moskalev I, Ellmark P, Dimberg A, Black P, Tötterman TH, Mangsbo SM.

Eur J Immunol. 2017 Feb;47(2):385-393. doi: 10.1002/eji.201646583. Epub 2016 Dec 13.

3.

Locally delivered CD40 agonist antibody accumulates in secondary lymphoid organs and eradicates experimental disseminated bladder cancer.

Sandin LC, Orlova A, Gustafsson E, Ellmark P, Tolmachev V, Tötterman TH, Mangsbo SM.

Cancer Immunol Res. 2014 Jan;2(1):80-90. doi: 10.1158/2326-6066.CIR-13-0067. Epub 2013 Oct 21.

4.

Local CTLA4 blockade effectively restrains experimental pancreatic adenocarcinoma growth in vivo.

Sandin LC, Eriksson F, Ellmark P, Loskog AS, Tötterman TH, Mangsbo SM.

Oncoimmunology. 2014 Jan 1;3(1):e27614. Epub 2014 Jan 16.

5.

Local immunotherapy based on agonistic CD40 antibodies effectively inhibits experimental bladder cancer.

Sandin LC, Tötterman TH, Mangsbo SM.

Oncoimmunology. 2014 Jan 1;3(1):e27400.

6.

Synergistic augmentation of CD40-mediated activation of antigen-presenting cells by amphiphilic poly(γ-glutamic acid) nanoparticles.

Broos S, Sandin LC, Apel J, Tötterman TH, Akagi T, Akashi M, Borrebaeck CA, Ellmark P, Lindstedt M.

Biomaterials. 2012 Sep;33(26):6230-9. doi: 10.1016/j.biomaterials.2012.05.011. Epub 2012 Jun 9.

PMID:
22687756
7.

Enhanced tumor eradication by combining CTLA-4 or PD-1 blockade with CpG therapy.

Mangsbo SM, Sandin LC, Anger K, Korman AJ, Loskog A, Tötterman TH.

J Immunother. 2010 Apr;33(3):225-35. doi: 10.1097/CJI.0b013e3181c01fcb.

PMID:
20445343
8.

Local AdCD40L gene therapy is effective for disseminated murine experimental cancer by breaking T-cell tolerance and inducing tumor cell growth inhibition.

Lindqvist C, Sandin LC, Fransson M, Loskog A.

J Immunother. 2009 Oct;32(8):785-92. doi: 10.1097/CJI.0b013e3181acea69.

PMID:
19752755

Supplemental Content

Loading ...
Support Center